BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

What time is it?” Cheryl Miller asks her husband, John. He wants to answer, but his wife has already asked him that question ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a high estimate of $300.00 and a low estimate of $180.00. Highlighting a 8.24 ...

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...

Recently, Eisai and Biogen announced the approval of LEQEMBI in Mexico for early Alzheimer's treatment, following successful Phase 3 trials. This approval, along with ongoing reviews in 16 other ...

Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...

The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the ...

BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...